Skip to main content
Have a personal or library account? Click to login
Transcatheter Aortic Valve Implantation: Long-Term Outcomes and Durability Cover

Transcatheter Aortic Valve Implantation: Long-Term Outcomes and Durability

Open Access
|May 2023

References

  1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):16951705. doi: 10.1056/NEJMoa1814052
  2. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):17061715. doi: 10.1056/NEJMoa1816885
  3. Otto CM, Nishimura RA, Bonow RO, et al.; Writing Committee Members. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25e197. doi: 10.1016/j.jacc.2020.11.018
  4. Otto CM, Kumbhani DJ, Alexander KP, et al. 2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2017 Mar 14;69(10):13131346. doi: 10.1016/j.jacc.2016.12.006
  5. Khan AA, Murtaza G, Khalid MF, Khattak F. Risk Stratification for Transcatheter Aortic Valve Replacement. Cardiol Res. 2019 Dec;10(6):323330. doi: 10.14740/cr966
  6. Barbash IM, Waksman R. Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the Edwards SAPIEN™ transcatheter heart valve. Circulation. 2012 Jan 24;125(3):5505. doi: 10.1161/CIRCULATIONAHA.111.059873
  7. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597607. doi: 10.1056/NEJMoa1008232
  8. Kapadia SR, Leon MB, Makkar RR, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015 Jun 20;385(9986):248591. doi: 10.1016/S0140-6736(15)60290-2
  9. Arnold SV, Petrossian G, Reardon MJ, et al. Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial. Circ Cardiovasc Interv. 2021 Jun;14(6):e010258. doi: 10.1161/CIRCINTERVENTIONS.120.010258
  10. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015 Jun 20;385(9986):247784. doi: 10.1016/S0140-6736(15)60308-7
  11. Gleason TG, Reardon MJ, Popma JJ, et al. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. J Am Coll Cardiol. 2018 Dec 4;72(22):26872696. doi: 10.1016/j.jacc.2018.08.2146
  12. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016 Apr 28;374(17):160920. doi: 10.1056/NEJMoa1514616
  13. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017 Apr 6;376(14):13211331. doi: 10.1056/NEJMoa1700456
  14. Makkar RR, Thourani VH, Mack MJ, et al. Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. N Engl J Med. 2020 Jan 29;382(9):799809. doi: 10.1056/NEJMoa1910555
  15. Tctmd.com [Internet]. Beverly Hills, CA: Cardiovascular Research Foundation; c2023. Kodali S. Sapien 3 TAVR versus surgery in intermediate-risk patients: a propensity score-matched analysis of 5-year outcomes; 2020 Jun 21 [cited 2023 Apr 26]. Available from: https://www.tctmd.com/slide/sapien-3-transcatheter-aortic-valve-replacement-compared-surgery-intermediate-risk-patients-0
  16. Van Mieghem NM, Deeb GM, Søndergaard L, et al. Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial. JAMA Cardiol. 2022 Oct 1;7(10):10001008. doi: 10.1001/jamacardio.2022.2695
  17. Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk. J Am Coll Cardiol. 2021 Mar 9;77(9):11491161. doi: 10.1016/j.jacc.2020.12.052
  18. Forrest JK, Deeb GM, Yakubov SJ, et al. Three-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis. J Am Coll Cardiol. 2023 Feb 24;S0735–1097(23)004114. doi: 10.1016/j.jacc.2023.02.017
  19. Jørgensen TH, Thyregod HGH, Ihlemann N, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J. 2021 Aug 7;42(30):29122919. doi: 10.1093/eurheartj/ehab375
  20. Chan V, Malas T, Lapierre H, et al. Reoperation of left heart valve bioprostheses according to age at implantation. Circulation. 2011 Sep 13;124(11 Suppl):S7580. doi: 10.1161/CIRCULATIONAHA.110.011973
  21. Etnel JRG, Huygens SA, Grashuis P, et al. Bioprosthetic Aortic Valve Replacement in Nonelderly Adults: A Systematic Review, Meta-Analysis, Microsimulation. Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e005481. doi: 10.1161/CIRCOUTCOMES.118.005481
  22. Huygens SA, Mokhles MM, Hanif M, et al. Contemporary outcomes after surgical aortic valve replacement with bioprostheses and allografts: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2016 Oct;50(4):605616. doi: 10.1093/ejcts/ezw101
  23. Manji RA, Menkis AH, Ekser B, Cooper DKC. The future of bioprosthetic heart valves. Indian J Med Res. 2012;135(2):1501
  24. Xue Y, Kossar AP, Abramov A, et al. Age-related enhanced degeneration of bioprosthetic valves due to leaflet calcification, tissue crosslinking, and structural changes. Cardiovasc Res. 2023 Mar 17;119(1):302315. doi: 10.1093/cvr/cvac002
  25. Brennan JM, Edwards FH, Zhao Y, et al.; Developing Evidence to Inform Decisions About Effectiveness–Aortic Valve Replacement (DEcIDE AVR) Research Team. Long-term survival after aortic valve replacement among high-risk elderly patients in the United States: insights from the Society of Thoracic Surgeons Adult Cardiac Surgery Database, 1991 to 2007. Circulation. 2012 Sep 25;126(13):16219. doi: 10.1161/CIRCULATIONAHA.112.091371
  26. Rodriguez-Gabella T, Voisine P, Puri R, Pibarot P, Rodés-Cabau J. Aortic Bioprosthetic Valve Durability: Incidence, Mechanisms, Predictors, and Management of Surgical and Transcatheter Valve Degeneration. J Am Coll Cardiol. 2017 Aug 22;70(8):10131028. doi: 10.1016/j.jacc.2017.07.715
  27. Mylotte D, Andalib A, Thériault-Lauzier P, et al. Transcatheter heart valve failure: a systematic review. Eur Heart J. 2015 Jun 1;36(21):130627. doi: 10.1093/eurheartj/ehu388
  28. Costa G, Criscione E, Todaro D, Tamburino C, Barbanti M. Long-term Transcatheter Aortic Valve Durability. Interv Cardiol. 2019 May 21;14(2):6269. doi: 10.15420/icr.2019.4.2
  29. Barbanti M, Tamburino C. Late degeneration of transcatheter aortic valves: pathogenesis and management. EuroIntervention. 2016 Sep 18;12(Y):Y336. doi: 10.4244/EIJV12SYA8
  30. Puri R, Auffret V, Rodés-Cabau J. Bioprosthetic Valve Thrombosis. J Am Coll Cardiol. 2017 May 2;69(17):21932211. doi: 10.1016/j.jacc.2017.02.051
  31. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017 Jun 17;389(10087):23832392. doi: 10.1016/S0140-6736(17)30757-2
  32. Makkar RR, Blanke P, Leipsic J, et al. Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves: PARTNER 3 Cardiac Computed Tomography Substudy. J Am Coll Cardiol. 2020 Jun 23;75(24):30033015. doi: 10.1016/j.jacc.2020.04.043
  33. Blanke P, Leipsic JA, Popma JJ, et al. Bioprosthetic Aortic Valve Leaflet Thickening in the Evolut Low Risk Sub-Study. J Am Coll Cardiol. 2020 May 19;75(19):24302442. doi: 10.1016/j.jacc.2020.03.022
  34. Christ T, Claus B, Borck R, Konertz W, Grubitzsch H. The St. Jude Toronto stentless bioprosthesis: up to 20 years follow-up in younger patients. Heart Surg Forum. 2015 Aug 30;18(4):E12933. doi: 10.1532/hsf.1252
  35. David TE, Feindel CM, Bos J, Ivanov J, Armstrong S. Aortic valve replacement with Toronto SPV bioprosthesis: optimal patient survival but suboptimal valve durability. J Thorac Cardiovasc Surg. 2008 Jan;135(1):1924. doi: 10.1016/j.jtcvs.2007.04.068
  36. Bach DS, Kon ND. Long-term clinical outcomes 15 years after aortic valve replacement with the Freestyle stentless aortic bioprosthesis. Ann Thorac Surg. 2014 Feb;97(2):54451. doi: 10.1016/j.athoracsur.2013.08.047
  37. Martinsson A, Nielsen SJ, Milojevic M, et al. Life Expectancy After Surgical Aortic Valve Replacement. J Am Coll Cardiol. 2021 Nov 30;78(22):21472157. doi: 10.1016/j.jacc.2021.09.861
  38. Salaun E, Clavel MA, Rodés-Cabau J, Pibarot P. Bioprosthetic aortic valve durability in the era of transcatheter aortic valve implantation. Heart. 2018 Aug;104(16):13231332. doi: 10.1136/heartjnl-2017-311582
  39. Fatima B, Mohananey D, Khan FW, et al. Durability Data for Bioprosthetic Surgical Aortic Valve: A Systematic Review. JAMA Cardiol. 2019 Jan 1;4(1):7180. doi: 10.1001/jamacardio.2018.4045
  40. Forcillo J, Pellerin M, Perrault LP, et al. Carpentier-Edwards pericardial valve in the aortic position: 25-years experience. Ann Thorac Surg. 2013 Aug;96(2):48693. doi: 10.1016/j.athoracsur.2013.03.032
  41. Bourguignon T, El Khoury R, Candolfi P, et al. Very Long-Term Outcomes of the Carpentier-Edwards Perimount Aortic Valve in Patients Aged 60 or Younger. Ann Thorac Surg. 2015 Sep;100(3):8539. doi: 10.1016/j.athoracsur.2015.03.105
  42. Yankah CA, Pasic M, Musci M, et al. Aortic valve replacement with the Mitroflow pericardial bioprosthesis: durability results up to 21 years. J Thorac Cardiovasc Surg. 2008 Sep;136(3):68896. doi: 10.1016/j.jtcvs.2008.05.022
  43. Mykén PSU, Bech-Hansen O. A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg. 2009 Jan;137(1):7681. doi: 10.1016/j.jtcvs.2008.05.068
  44. Guenzinger R, Fiegl K, Wottke M, Lange RS. Twenty-Seven-Year Experience With the St. Jude Medical Biocor Bioprosthesis in the Aortic Position. Ann Thorac Surg. 2015 Dec;100(6):22206. doi: 10.1016/j.athoracsur.2015.06.027
  45. Sénage T, Le Tourneau T, Foucher Y, et al. Early structural valve deterioration of Mitroflow aortic bioprosthesis: mode, incidence, and impact on outcome in a large cohort of patients. Circulation. 2014 Dec 2;130(23):20122020. doi: 10.1161/CIRCULATIONAHA.114.010400
  46. Kalra A, Rehman H, Ramchandani M, et al. Early Trifecta valve failure: Report of a cluster of cases from a tertiary care referral center. J Thorac Cardiovasc Surg. 2017 Oct;154(4):12351240. doi: 10.1016/j.jtcvs.2017.05.044
  47. Capodanno D, Petronio AS, Prendergast B, et al. S of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017 Dec 1;38(45):33823390. doi: 10.1093/eurheartj/ehx303
  48. Dvir D, Bourguignon T, Otto CM, et al. Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. Circulation. 2018 Jan 23;137(4):388399. doi: 10.1161/CIRCULATIONAHA.117.030729
  49. VARC-3 WRITING COMMITTEE, Généreux P, Piazza N, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021 May 14;42(19):18251857. doi: 10.1093/eurheartj/ehaa799
  50. Pibarot P, Ternacle J, Jaber WA, et al. Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial. J Am Coll Cardiol. 2020;76(16):18301843. doi: 10.1016/j.jacc.2020.08.049
  51. Salaun E, Mahjoub H, Girerd N, et al. Rate, Timing, Correlates, and Outcomes of Hemodynamic Valve Deterioration After Bioprosthetic Surgical Aortic Valve Replacement. Circulation. 2018 Sep 4;138(10):971985. doi: 10.1161/CIRCULATIONAHA.118.035150
  52. Salaun E, Mahjoub H, Dahou A, et al. Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves. J Am Coll Cardiol. 2018 Jul 17;72(3):241251. doi: 10.1016/j.jacc.2018.04.064
  53. Didier R, Eltchaninoff H, Donzeau-Gouge P, et al. Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk Patients. Circulation. 2018 Dec 4;138(23):25972607. doi: 10.1161/CIRCULATIONAHA.118.036866
  54. Blackman DJ, Saraf S, MacCarthy PA, et al. Long-Term Durability of Transcatheter Aortic Valve Prostheses. J Am Coll Cardiol. 2019 Feb 12;73(5):537545. doi: 10.1016/j.jacc.2018.10.078
  55. Durand E, Sokoloff A, Urena-Alcazar M, et al. Assessment of Long-Term Structural Deterioration of Transcatheter Aortic Bioprosthetic Valves Using the New European Definition. Circ Cardiovasc Interv. 2019 Apr;12(4):e007597. doi: 10.1161/CIRCINTERVENTIONS.118.007597
  56. Søndergaard L, Ihlemann N, Capodanno D, et al. Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk. J Am Coll Cardiol. 2019 Feb 12;73(5):546553. doi: 10.1016/j.jacc.2018.10.083
  57. Richter I, Thiele H, Abdel-Wahab M. Durability of Transcatheter Heart Valves: Standardized Definitions and Available Data. J Clin Med Res. 2021 Sep 16;10(18):4180. doi: 10.3390/jcm10184180
  58. O’Hair D, Yakubov SJ, Grubb KJ, et al. Structural Valve Deterioration After Self-Expanding Transcatheter or Surgical Aortic Valve Implantation in Patients at Intermediate or High Risk. JAMA Cardiol. 2023 Feb 1;8(2):111119. doi: 10.1001/jamacardio.2022.4627
  59. Russo G, Tang GHL, Sangiorgi G, et al. Lifetime Management of Aortic Stenosis: Transcatheter Versus Surgical Treatment for Young and Low-Risk Patients. Circ Cardiovasc Interv. 2022 Nov;15(11):915927. doi: 10.1161/CIRCINTERVENTIONS.122.012388
DOI: https://doi.org/10.14797/mdcvj.1201 | Journal eISSN: 1947-6108
Language: English
Page range: 15 - 25
Submitted on: Mar 24, 2023
Accepted on: Apr 27, 2023
Published on: May 16, 2023
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2023 Parth V. Desai, Sachin S. Goel, Neal S. Kleiman, Michael J. Reardon, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.